Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma
Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.
Source: onclive.com
Melanoma Research Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Melanoma Research Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Melanoma Research Program Today - Breaking & Trending Today
Orlucent Demonstrates Accurate, Non-Invasive Detection in vivo of Melanoma-Related Activity Using First-in-Kind Handheld Mole Imaging System
/PRNewswire/ -- In a first-in-human study, researchers at Orlucent, Inc. have demonstrated the viability of a novel handheld point-of-care molecular Skin...
Source: prnewswire.com
ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma
Jeffrey S. Weber, MD, PhD, highlighted key efficacy findings from the mRNA-4157-P201/KEYNOTE-942 trial, expanded on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma, and underscored the importance of continued research on mRNA vaccines paired with standard PD-1 therapy across cancer types.
Source: onclive.com
Turnstone Biologics Corp. Reports Third Quarter 2023
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights...
Source: globenewswire.com
Dr Weber on Survival Outcomes With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma
Jeffrey S. Weber, MD, PhD, discusses findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial of mRNA-4157 in combination with pembrolizumab in resected high-risk melanoma.
Source: onclive.com